Table 4.
Univariate and multivariable Logistic analysis of BCS benefit for young breast cancer patients.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Variables | HR* | 95%CI | P-value | HR* | 95%CI | P-value |
| Age | ||||||
| 1.004 | (1.001, 1.007) | 0.009 | 1.004 | (1.002, 1.007) | 0.002 | |
| Race | ||||||
| Black | Reference | |||||
| Other | 1.006 | (0.972, 1.042) | 0.724 | |||
| White | 0.964 | (0.939, 0.989) | 0.005 | |||
| Laterality | ||||||
| Left | Reference | |||||
| Right | 1.011 | (0.993, 1.03) | 0.229 | |||
| Marital | ||||||
| No | Reference | Reference | ||||
| Yes | 0.959 | (0.941, 0.977) | 0.000 | 0.946 | (0.93, 0.962) | 0.000 |
| Grade | ||||||
| I | Reference | Reference | ||||
| II | 0.868 | (0.835, 0.902) | 0.000 | 0.968 | (0.935, 1.002) | 0.067 |
| III | 0.889 | (0.857, 0.923) | 0.000 | 1.002 | (0.968, 1.037) | 0.900 |
| IV | 0.951 | (0.882, 1.026) | 0.196 | 1.018 | (0.952, 1.089) | 0.595 |
| Histology | ||||||
| IDC | Reference | |||||
| ILC | 0.871 | (0.806, 0.941) | 0.001 | |||
| Other | 1.023 | (0.991, 1.056) | 0.166 | |||
| T stage | ||||||
| T1 | Reference | Reference | ||||
| T2 | 0.926 | (0.909, 0.944) | 0.000 | 0.945 | (0.928,0.962) | 0.000 |
| T3 | 0.730 | (0.708, 0.753) | 0.000 | 0.743 | (0.722,0.765) | 0.000 |
| N stage | ||||||
| N0 | Reference | Reference | ||||
| N1 | 0.872 | (0.854, 0.889) | 0.000 | 0.884 | (0.868, 0.900) | 0.000 |
| N2 | 0.808 | (0.783, 0.834) | 0.000 | 0.785 | (0.762, 0.808) | 0.000 |
| N3 | 0.770 | (0.739, 0.803) | 0.000 | 0.775 | (0.746, 0.805) | 0.000 |
| Chemotherapy | ||||||
| No | Reference | Reference | ||||
| Yes | 0.946 | (0.924, 0.969) | 0.000 | 0.928 | (0.907, 0.950) | 0.000 |
| Radiation | ||||||
| No | Reference | Reference | ||||
| Yes | 1.382 | (1.358, 1.406) | 0.000 | 1.459 | (1.435, 1.484) | 0.000 |
| Subtype | ||||||
| HR-/HER2- | Reference | Reference | ||||
| HR-/HER2+ | 0.92 | (0.861, 0.983) | 0.014 | 0.972 | (0.917, 1.031) | 0.350 |
| HR+/HER2- | 0.992 | (0.956, 1.030) | 0.680 | 0.973 | (0.940, 1.008) | 0.126 |
| HR+/HER2+ | 0.969 | (0.925, 1.015) | 0.185 | 0.966 | (0.927, 1.008) | 0.109 |
| Not 2010+ | 1.152 | (1.114, 1.191) | 0.000 | 1.127 | (1.093, 1.162) | 0.000 |
BCS, Breast conserving surgery; IDC, Invasive ductal carcinoma; ILC, Invasive lobular carcinoma; HR, Hormone receptor; HER2, Human epidermal growth factor receptor 2; HR*, hazard ratio; CI, confidence interval.